Skip to main content
Erschienen in: Digestive Diseases and Sciences 5/2018

27.12.2017 | Original Article

Changing Epidemiology of Upper Gastrointestinal Hemorrhage in the Last Decade: A Nationwide Analysis

verfasst von: Brandon A. Wuerth, Don C. Rockey

Erschienen in: Digestive Diseases and Sciences | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Upper gastrointestinal hemorrhage (UGIH) is common and carries substantial mortality requiring frequent hospitalizations.

Aim

To investigate trends in etiology and outcome of UGIH in hospitalized patients in the USA.

Methods

Retrospective, observational cohort study of the Nationwide Inpatient Sample from 2002 to 2012 was carried out. UGIH was identified in hospitalizations with a principle ICD-9-CM diagnosis of UGIH or secondary diagnosis of UGIH with a principal diagnosis of hematemesis, blood in stool, or gastrointestinal bleeding. Age 18 years or older was required for inclusion, and elective admissions and transferred patients were excluded.

Results

The hospitalization rate of UGIH in the USA decreased by 21% from 2002 to 2012, from 81 to 67 cases per 100,000 population (p < 0.01). The greatest declines occurred for gastritis and PUD, which decreased by 55 and 30%, respectively (p < 0.01). There were increases in neoplasm, Dieulafoy lesions, angiodysplasia, and esophagitis, which increased by 50, 33, 32 and 20%, respectively (p < 0.01). The all-cause inpatient mortality rate of UGIH decreased 28% from 2.6 per 100 cases in 2002 to 1.9 in 2012 (p < 0.01). The greatest decline occurred for esophagitis, Mallory–Weiss tear, and neoplasm, which decreased by 39% (p < 0.01), 36% (p = 0.02), and 36% (p < 0.01), respectively. The rate of hospitalization for bleeding caused by esophageal varices remained constant and low (approximately 2%) throughout the study period; the mortality for esophageal varices also remained constant at 6–7%.

Conclusions

The epidemiology of UGIH hemorrhage appears to be shifting, with a decline in PUD and gastritis; an increase in hospitalization rate for neoplasm, Dieulafoy lesions, angiodysplasia, and esophagitis; and a reduction in overall mortality. The decreasing hospitalization rate and mortality rate of UGIH suggest population trends in use of treatments for PUD, improved hemostatic techniques, and overall care.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Esrailian E, Gralnek IM. Nonvariceal upper gastrointestinal bleeding: epidemiology and diagnosis. Gastroenterol Clin North Am. 2005;34:589–605.CrossRefPubMed Esrailian E, Gralnek IM. Nonvariceal upper gastrointestinal bleeding: epidemiology and diagnosis. Gastroenterol Clin North Am. 2005;34:589–605.CrossRefPubMed
2.
Zurück zum Zitat Laine L, Yang H, Chang SC, et al. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol. 2012;107:1190–1195. (quiz 1196).CrossRefPubMed Laine L, Yang H, Chang SC, et al. Trends for incidence of hospitalization and death due to GI complications in the United States from 2001 to 2009. Am J Gastroenterol. 2012;107:1190–1195. (quiz 1196).CrossRefPubMed
3.
Zurück zum Zitat van Leerdam ME. Epidemiology of acute upper gastrointestinal bleeding. Best Pract Res Clin Gastroenterol. 2008;22:209–224.CrossRefPubMed van Leerdam ME. Epidemiology of acute upper gastrointestinal bleeding. Best Pract Res Clin Gastroenterol. 2008;22:209–224.CrossRefPubMed
4.
Zurück zum Zitat Rockall TA, Logan RF, Devlin HB, et al. Variation in outcome after acute upper gastrointestinal haemorrhage. The national audit of acute upper gastrointestinal haemorrhage. Lancet. 1995;346:346–350.CrossRefPubMed Rockall TA, Logan RF, Devlin HB, et al. Variation in outcome after acute upper gastrointestinal haemorrhage. The national audit of acute upper gastrointestinal haemorrhage. Lancet. 1995;346:346–350.CrossRefPubMed
5.
Zurück zum Zitat Rotondano G. Epidemiology and diagnosis of acute nonvariceal upper gastrointestinal bleeding. Gastroenterol Clin North Am. 2014;43:643–663.CrossRefPubMed Rotondano G. Epidemiology and diagnosis of acute nonvariceal upper gastrointestinal bleeding. Gastroenterol Clin North Am. 2014;43:643–663.CrossRefPubMed
6.
Zurück zum Zitat Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol. 1995;90:206–210.PubMed Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol. 1995;90:206–210.PubMed
7.
Zurück zum Zitat van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol. 2003;98:1494–1499.CrossRefPubMed van Leerdam ME, Vreeburg EM, Rauws EA, et al. Acute upper GI bleeding: did anything change? Time trend analysis of incidence and outcome of acute upper GI bleeding between 1993/1994 and 2000. Am J Gastroenterol. 2003;98:1494–1499.CrossRefPubMed
8.
Zurück zum Zitat Cook DJ, Guyatt GH, Salena BJ, et al. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Gastroenterology. 1992;102:139–148.CrossRefPubMed Cook DJ, Guyatt GH, Salena BJ, et al. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Gastroenterology. 1992;102:139–148.CrossRefPubMed
9.
Zurück zum Zitat Bardou M, Toubouti Y, Benhaberou-Brun D, et al. Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther. 2005;21:677–686.CrossRefPubMed Bardou M, Toubouti Y, Benhaberou-Brun D, et al. Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Aliment Pharmacol Ther. 2005;21:677–686.CrossRefPubMed
10.
Zurück zum Zitat Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2006;3:CD002094. Leontiadis GI, Sharma VK, Howden CW. Proton pump inhibitor treatment for acute peptic ulcer bleeding. Cochrane Database Syst Rev. 2006;3:CD002094.
11.
Zurück zum Zitat HCUP Databases. Healthcare cost and utilization project (HCUP). Nationwide inpatient sample (NIS) aLdaahwh-uag. HCUP Databases. Healthcare Cost and Utilization Project (HCUP). Nationwide Inpatient Sample (NIS), 2002 and 2012. Limited database available at: http://www.hcup-us.ahrq.gov. HCUP Databases. Healthcare cost and utilization project (HCUP). Nationwide inpatient sample (NIS) aLdaahwh-uag. HCUP Databases. Healthcare Cost and Utilization Project (HCUP). Nationwide Inpatient Sample (NIS), 2002 and 2012. Limited database available at: http://​www.​hcup-us.​ahrq.​gov.
13.
Zurück zum Zitat Abougergi MS, Travis AC, Saltzman JR. The in-hospital mortality rate for upper GI hemorrhage has decreased over 2 decades in the United States: a nationwide analysis. Gastrointest Endosc. 2015;81(882–8):e1. Abougergi MS, Travis AC, Saltzman JR. The in-hospital mortality rate for upper GI hemorrhage has decreased over 2 decades in the United States: a nationwide analysis. Gastrointest Endosc. 2015;81(882–8):e1.
14.
Zurück zum Zitat Kim JJ, Sheibani S, Park S, et al. Causes of bleeding and outcomes in patients hospitalized with upper gastrointestinal bleeding. J Clin Gastroenterol. 2014;48:113–118.CrossRefPubMed Kim JJ, Sheibani S, Park S, et al. Causes of bleeding and outcomes in patients hospitalized with upper gastrointestinal bleeding. J Clin Gastroenterol. 2014;48:113–118.CrossRefPubMed
15.
Zurück zum Zitat Balderas V, Bhore R, Lara LF, et al. The hematocrit level in upper gastrointestinal hemorrhage: safety of endoscopy and outcomes. Am J Med. 2011;124:970–976.CrossRefPubMed Balderas V, Bhore R, Lara LF, et al. The hematocrit level in upper gastrointestinal hemorrhage: safety of endoscopy and outcomes. Am J Med. 2011;124:970–976.CrossRefPubMed
16.
Zurück zum Zitat Guntipalli P, Chason R, Elliott A, et al. Upper gastrointestinal bleeding caused by severe esophagitis: a unique clinical syndrome. Dig Dis Sci. 2014;59:2997–3003.CrossRefPubMed Guntipalli P, Chason R, Elliott A, et al. Upper gastrointestinal bleeding caused by severe esophagitis: a unique clinical syndrome. Dig Dis Sci. 2014;59:2997–3003.CrossRefPubMed
17.
Zurück zum Zitat Lyles T, Elliott A, Rockey DC. A risk scoring system to predict in-hospital mortality in patients with cirrhosis presenting with upper gastrointestinal bleeding. J Clin Gastroenterol. 2014;48:712–720.CrossRefPubMed Lyles T, Elliott A, Rockey DC. A risk scoring system to predict in-hospital mortality in patients with cirrhosis presenting with upper gastrointestinal bleeding. J Clin Gastroenterol. 2014;48:712–720.CrossRefPubMed
18.
Zurück zum Zitat Perez-Aisa MA, Del Pino D, Siles M, et al. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2005;21:65–72.CrossRefPubMed Perez-Aisa MA, Del Pino D, Siles M, et al. Clinical trends in ulcer diagnosis in a population with high prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther. 2005;21:65–72.CrossRefPubMed
19.
Zurück zum Zitat Raiford DS, Perez Gutthann S, Garcia Rodriguez LA. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology. 1996;7:101–104.CrossRefPubMed Raiford DS, Perez Gutthann S, Garcia Rodriguez LA. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Epidemiology. 1996;7:101–104.CrossRefPubMed
20.
Zurück zum Zitat Cattaruzzi C, Troncon MG, Agostinis L, et al. Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database. J Clin Epidemiol. 1999;52:499–502.CrossRefPubMed Cattaruzzi C, Troncon MG, Agostinis L, et al. Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Sanitario Regionale database. J Clin Epidemiol. 1999;52:499–502.CrossRefPubMed
21.
Zurück zum Zitat Pisa F, Castellsague J, Drigo D, et al. Accuracy of international classification of diseases, 9th revision, clinical modification codes for upper gastrointestinal complications varied by position and age: a validation study in a cohort of nonsteroidal anti-inflammatory drugs users in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf. 2013;22:1195–1204.CrossRefPubMed Pisa F, Castellsague J, Drigo D, et al. Accuracy of international classification of diseases, 9th revision, clinical modification codes for upper gastrointestinal complications varied by position and age: a validation study in a cohort of nonsteroidal anti-inflammatory drugs users in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf. 2013;22:1195–1204.CrossRefPubMed
22.
Zurück zum Zitat Cooper GS, Chak A, Lloyd LE, et al. The accuracy of diagnosis and procedural codes for patients with upper GI hemorrhage. Gastrointest Endosc. 2000;51:423–426.CrossRefPubMed Cooper GS, Chak A, Lloyd LE, et al. The accuracy of diagnosis and procedural codes for patients with upper GI hemorrhage. Gastrointest Endosc. 2000;51:423–426.CrossRefPubMed
Metadaten
Titel
Changing Epidemiology of Upper Gastrointestinal Hemorrhage in the Last Decade: A Nationwide Analysis
verfasst von
Brandon A. Wuerth
Don C. Rockey
Publikationsdatum
27.12.2017
Verlag
Springer US
Erschienen in
Digestive Diseases and Sciences / Ausgabe 5/2018
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4882-6

Weitere Artikel der Ausgabe 5/2018

Digestive Diseases and Sciences 5/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.